Alpha-1 Antitrypsin Deficiency (A1AD) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Alpha-1 Antitrypsin Deficiency (A1AD) – Drugs In Development, 2024 report and make more profitable business decisions.
Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes, and infections.
The Alpha-1 Antitrypsin Deficiency (A1AD) drugs in development market research report provide comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Alpha-1 Antitrypsin Deficiency (A1AD) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Alpha-1 Antitrypsin Deficiency (A1AD) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 45 molecules, with 45 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Alpha-1 Antitrypsin Deficiency (A1AD) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Alpha-1 Antitrypsin Deficiency (A1AD) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Alpha-1 Antitrypsin Deficiency (A1AD) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
4D Molecular Therapeutics IncADARx Pharmaceuticals Inc
Airna Corp inc
AlveoGene Ltd
Apic Bio Inc
Arrowhead Pharmaceuticals Inc
Beam Therapeutics Inc
BioMarin Pharmaceutical Inc
Bioviz Technologies Pvt Ltd
Caravella Biopharma SA
Celon Pharma SA
Centessa Pharmaceuticals Plc
EDIRNA Inc
Editas Medicine Inc
Epicrispr Biotechnologies Inc
Evolve Biologics Inc
Gain Therapeutics Inc
Graphite Bio Inc
Grifols SA
GSK plc
Hepatx Corp
Inhibrx Inc
Intellia Therapeutics Inc
International Stem Cell Corp
Kamada Pharmaceuticals
Korro Bio Ops Inc
Krystal Biotech Inc
Lexeo Therapeutics Inc
Liminal BioSciences Inc
Logicbio Therapeutics Inc
Mereo Biopharma Group Plc
Moderna Inc
NeuImmune Inc
Novo Nordisk AS
Peak Bio Inc
PlantForm Corp
Shape Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Vertex Pharmaceuticals Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Alpha-1 Antitrypsin Deficiency (A1AD) reports